BURLINGAME, CA, Genesis Therapeutics, harnessing AI to create medicines for patients with severe diseases, announced a $200 million Oversubscribed Series B funding round.
Genesis Therapeutics, harnessing AI to create medicines for patients with severe diseases, announced a $200 million Oversubscribed Series B funding round led by Andreessen Horowitz, with participation from new investors, Fidelity Management & Research Company, BlackRock, and NVentures, with participation from existing investors, T. Rowe Price Associates, Rock Springs Capital, Radical Ventures, and Menlo Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
